ArticleResearch and practice in thrombosis and haemostasis2026
Management and outcomes in patients with cryptogenic stroke and weakly positive antiphospholipid antibodies.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk of recurrent stroke and optimal antithrombotic strategy for cryptogenic stroke in patients with weakly positive antiphospholipid antibodies (aPLs) are uncertain. Objectives: The aim of this study was to describe antithrombotic practice patterns and clinical outcomes, comparing patients with weakly positive aPLs with those with strongly positive aPLs. Methods: This retrospective cohort study included patients who received care in the University of Pennsylvania Health System between March 1, 2017, and December 31, 2023, with index cryptogenic stroke or transient ischemic attack, positive aPLs persisting for ≥12 weeks, and not on antithrombotic therapy prior to the index event. We evaluated antithrombotic therapy recommendations using univariate hypothesis testing and clinical outcomes including stroke recurrence rate and major bleeding events using survival analyses, comparing patients with weakly positive aPLs and those with strongly positive aPLs. Results: We identified 47 patients who met eligibility criteria, 30 weakly positive and 17 strongly positive. Warfarin was recommended less often ( Conclusion: Most patients with cryptogenic stroke and weakly positive aPLs received antiplatelet agents. Patients with weakly positive aPLs had a lower incidence of recurrent stroke compared with patients with strongly positive aPLs, despite less intensive antithrombotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.